9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies

Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies

Chronic Kidney Disease (CKD) affects more than 1 in 7 adults in the United States (~37 million people) and represents a major multiplier of cardiovascular morbidity and all-cause mortality. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification requires a thorough mastery of KDIGO (Kidney Disease: Improving Global Outcomes) diagnostic criteria and staging, precise interpretation of the urine albumin-to-creatinine ratio (UACR), evidence-based implementation of multi-drug renoprotective regimens, vigilant surveillance and treatment of CKD complications, and timely referral for nephrology co-management and renal replacement therapy (RRT) planning.

---

1. Definition, Diagnostic Criteria & Pathophysiology of CKD

KDIGO Diagnostic Definition

CKD is defined as abnormalities of kidney structure or function persisting for at least 3 continuous months with implications for health. A transient decline in glomerular filtration rate (GFR) or temporary proteinuria resulting from acute illness, fever, or volume depletion does not constitute CKD.

+-----------------------------------------------------------------------------+
|                        KDIGO CRITERIA FOR CKD (>= 3 MONTHS)                 |
|                                                                             |
|   EITHER OF THE FOLLOWING CRITERIA PRESENT PERSISTENTLY FOR > 3 MONTHS:      |
|                                                                             |
|   1. DECREASED GLOMERULAR FILTRATION RATE:                                  |
|      - eGFR < 60 mL/min/1.73 m2 (Stages G3a, G3b, G4, or G5)                |
|                                                                             |
|                                    OR                                       |
|                                                                             |
|   2. ONE OR MORE MARKERS OF KIDNEY DAMAGE:                                  |
|      - Albuminuria: Urine Albumin-to-Creatinine Ratio (UACR) >= 30 mg/g     |
|        (or >= 3 mg/mmol; 24-hr urine albumin >= 30 mg/24 hr).               |
|      - Urine Sediment Abnormalities: Persistent dysmorphic RBCs, RBC casts, |
|        WBC casts, granular casts, or fatty casts / oval fat bodies.         |
|      - Tubular Disorders: Renal tubular acidosis, nephrogenic DI, Bartter.  |
|      - Histopathological Abnormalities: Biopsy-proven glomerulonephritis,   |
|        amyloidosis, interstitial fibrosis, or Kimmelstiel-Wilson nodules.   |
|      - Structural Abnormalities on Imaging: Polycystic kidneys, hydroneph-  |
|        rosis, renal artery stenosis, cortical thinning, small echogenic kidneys.|
|      - History of Kidney Transplantation.                                   |
+-----------------------------------------------------------------------------+

Primary Etiologies of CKD in Adults

1. Diabetic Kidney Disease (DKD / Diabetic Nephropathy): Leading cause (~40–50% of ESRD cases). Driven by chronic hyperglycemia, advanced glycation end-products (AGEs), reactive oxygen species, and hyperfiltration.
2. Hypertensive Nephrosclerosis: Second leading cause (~25–30%). Chronic systemic hypertension transmits elevated pressures into renal microvasculature, producing medial hypertrophy, hyaline arteriolosclerosis, glomerular ischemia, and focal segmental glomerulosclerosis.
3. Glomerulonephritis: IgA Nephropathy (Berger disease; most common primary glomerulonephritis worldwide), Membranous Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), Lupus Nephritis, and ANCA-associated vasculitis.
4. Autosomal Dominant Polycystic Kidney Disease (ADPKD): Mutations in PKD1 (chromosome 16) or PKD2 (chromosome 4) causing bilateral progressive cystic enlargement.
5. Chronic Tubulointerstitial Nephritis & Toxicities: Chronic NSAID exposure, calcineurin inhibitors (cyclosporine, tacrolimus), chronic lithium therapy, heavy metals, or recurrent pyelonephritis/obstructive uropathy.

Pathophysiological Cascade: Hyperfiltration & Glomerular Sclerosis

Regardless of the initiating insult, the progressive loss of functional nephrons triggers compensatory adaptive mechanisms in surviving nephrons that ultimately prove maladaptive.

+-----------------------------------------------------------------------------+
|                  MALADAPTIVE NEPHRON LOSS & PROGRESSION CASCADE             |
|                                                                             |
|   Primary Renal Insult (e.g., Diabetes, Hypertension, Glomerulonephritis)   |
|                                     |                                       |
|                                     v                                       |
|                  Loss of Functional Nephron Mass (Nephron Loss)             |
|                                     |                                       |
|                                     v                                       |
|       Compensatory Hypertrophy & Hyperfiltration in Surviving Nephrons      |
|         - Preferential EFFERENT arteriolar vasoconstriction (Angiotensin II)|
|         - Afferent arteriolar vasodilation (Prostaglandins, Nitric Oxide)   |
|                                     |                                       |
|                                     v                                       |
|        Elevated Intraglomerular Capillary Hydrostatic Pressure (P_gc)       |
|                                     |                                       |
|                                     v                                       |
|         Disruption of Podocyte Slit Diaphragm & Glomerular Basement         |
|            Membrane (GBM) -> ACCELERATED ALBUMINURIA / PROTEINURIA          |
|                                     |                                       |
|                                     v                                       |
|          Filtered Albumin & Cytokines Trigger Proximal Tubular Injury       |
|                 -> Tubulointerstitial Inflammation & Fibrosis               |
|                                     |                                       |
|                                     v                                       |
|             GLOMERULOSCLEROSIS & PROGRESSIVE DECLINE IN eGFR                |
+-----------------------------------------------------------------------------+

---

2. KDIGO 2D Staging & Prognostic Risk Matrix (G1–G5 and A1–A3)

KDIGO guidelines mandate a two-dimensional classification system combining the GFR category (G1–G5) with the Albuminuria category (A1–A3). Staging solely by eGFR fails to capture the dramatic cardiovascular and renal risk imparted by albuminuria.

+---------------------------------------------------------------------------------------------------+
|                               KDIGO 2D PROGNOSTIC RISK MATRIX                                     |
|                                                                                                   |
|   GFR STAGES                    A1: Normal/Mild          A2: Moderate            A3: Severe       |
|   (mL/min/1.73 m2)              UACR < 30 mg/g           UACR 30-300 mg/g        UACR > 300 mg/g  |
|   ---------------------------------------------------------------------------------------------   |
|   G1: Normal/High (>= 90)       [ LOW RISK ]             [ MODERATE RISK ]       [ HIGH RISK ]    |
|   G2: Mildly Reduced (60-89)    [ LOW RISK ]             [ MODERATE RISK ]       [ HIGH RISK ]    |
|   G3a: Mild-to-Mod (45-59)      [ MODERATE RISK ]        [ HIGH RISK ]           [ VERY HIGH ]    |
|   G3b: Mod-to-Severe (30-44)    [ HIGH RISK ]            [ VERY HIGH RISK ]      [ VERY HIGH ]    |
|   G4: Severely Reduced (15-29)  [ VERY HIGH RISK ]       [ VERY HIGH RISK ]      [ VERY HIGH ]    |
|   G5: Kidney Failure (< 15)     [ VERY HIGH RISK ]       [ VERY HIGH RISK ]      [ VERY HIGH ]    |
+---------------------------------------------------------------------------------------------------+

Clinical Staging Categories & Terminology

• G1: Normal or high GFR ($\ge 90\text{ mL/min}/1.73\text{ m}^2$) — Requires structural damage (e.g., $UACR \ge 30\text{ mg/g}$) to be diagnosed as CKD.
• G2: Mildly decreased GFR ($60\text{--}89\text{ mL/min}/1.73\text{ m}^2$) — Requires structural damage to meet CKD definition.
• G3a: Mildly to moderately decreased GFR ($45\text{--}59\text{ mL/min}/1.73\text{ m}^2$).
• G3b: Moderately to severely decreased GFR ($30\text{--}44\text{ mL/min}/1.73\text{ m}^2$).
• G4: Severely decreased GFR ($15\text{--}29\text{ mL/min}/1.73\text{ m}^2$) — High risk of progression; mandate vascular access planning.
• G5: Kidney Failure / End-Stage Kidney Disease ($< 15\text{ mL/min}/1.73\text{ m}^2$ or dialysis dependency).

Albuminuria Quantification (UACR vs. 24-Hour Urine Collection)

• The random spot Urine Albumin-to-Creatinine Ratio (UACR) in an early morning specimen is the gold standard for clinical screening and monitoring. Spot UACR in $\text{mg/g}$ accurately correlates with 24-hour total albumin excretion in $\text{mg/24 hours}$:
  • A1 (Normal to Mildly Increased): $UACR < 30\text{ mg/g}$ ($< 3\text{ mg/mmol}$).
  • A2 (Moderately Increased): $UACR = 30\text{--}300\text{ mg/g}$ ($3\text{--}30\text{ mg/mmol}$). Note: The historical term "microalbuminuria" is deprecated by KDIGO/ADA; use "moderately increased albuminuria."
  • A3 (Severely Increased): $UACR > 300\text{ mg/g}$ ($> 30\text{ mg/mmol}$). Includes nephrotic range ($UACR > 2,200\text{ mg/g}$ or total proteinuria $> 3.5\text{ g/day}$). Historical term "macroalbuminuria" is deprecated.

---

3. Evidence-Based Renoprotective Pharmacotherapy

The management of CKD has evolved from passive monitoring to active multi-pathway pharmacotherapy aimed at slowing eGFR decline, reducing intraglomerular pressure, halting albuminuria, and lowering cardiovascular mortality.

+-----------------------------------------------------------------------------+
|              PILLARS OF EVIDENCE-BASED RENOPROTECTIVE PHARMACOTHERAPY       |
|                                                                             |
|   1. RAAS INHIBITION (ACEi or ARB Monotherapy)                              |
|      - Indication: Hypertension + Albuminuria (UACR >= 30 in DM; >= 300 in   |
|        non-DM; or >= 30 in non-DM if HTN present).                          |
|      - Action: Dilates efferent arteriole -> drops P_gc.                    |
|                                                                             |
|   2. SGLT2 INHIBITORS (Empagliflozin, Dapagliflozin, Canagliflozin)         |
|      - Indication: CKD with eGFR >= 20 mL/min/1.73 m2 + UACR >= 200 mg/g    |
|        (with or without Type 2 Diabetes; DAPA-CKD, EMPA-KIDNEY trials).     |
|      - Action: Restores tubuloglomerular feedback -> constricts afferent art.|
|                                                                             |
|   3. NON-STEROIDAL MRAs (Finerenone)                                        |
|      - Indication: T2D + CKD (eGFR >= 25 + UACR >= 30) on max tolerated      |
|        ACEi/ARB with serum K <= 4.8 mEq/L (FIDELIO-DKD, FIGARO-DKD).        |
|      - Action: Blocks mineralocorticoid receptor inflammation and fibrosis. |
|                                                                             |
|   4. GLP-1 RECEPTOR AGONISTS (Semaglutide, Dulaglutide)                     |
|      - Indication: T2D + CKD with inadequate glycemic control or high CV    |
|        risk (FLOW trial; reduces renal outcomes and CV mortality).          |
+-----------------------------------------------------------------------------+

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

• Mechanism: Angiotensin-Converting Enzyme Inhibitors (ACEi, e.g., Lisinopril, Enalapril) and Angiotensin II Receptor Blockers (ARBs, e.g., Losartan, Valsartan) selectively block Angiotensin II action on $\text{AT}_1$ receptors, causing preferential dilation of the efferent arteriole. This reduces intraglomerular capillary hydrostatic pressure ($P_{\text{gc}}$), diminishes glomerular mechanical shear stress, and halts podocyte detachment.
• Blood Pressure Targets: KDIGO recommends a target systolic blood pressure $< 120\text{ mmHg}$ (using standardized office measurement) when tolerated. The ADA recommends a target $< 130/80\text{ mmHg}$ for patients with diabetes and CKD.
• The "Acceptable Creatinine Bump" Rule: Following initiation or dose escalation of an ACEi or ARB, a transient acute drop in eGFR or a serum creatinine increase up to 30% from baseline is expected and represents a favorable hemodynamic reduction in glomerular hypertension.
  • Clinical Decision Rule: Do NOT discontinue the ACEi/ARB if creatinine rises $\le 30\%$ and stabilizes. Recheck labs in 2–4 weeks. Only reduce dose or discontinue if creatinine rises $>30\%$, if refractory hyperkalemia occurs ($K^+ > 5.5\text{--}6.0\text{ mEq/L}$ despite medical therapy), or if severe symptomatic hypotension develops.
  • A creatinine spike $>30\%$ suggests underlying bilateral renal artery stenosis (or unilateral stenosis in a solitary kidney) or severe intravascular volume depletion.
• Strict Contraindication: Dual RAAS Blockade (concurrent use of ACEi + ARB, or RAAS inhibitor + Direct Renin Inhibitor [Aliskiren]) is strictly contraindicated due to high risks of hyperkalemia, acute kidney injury, and hypotension without incremental cardiovascular or renal benefit (demonstrated in ONTARGET and VA NEPHRON-D trials).

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Mechanism of Renoprotection: SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) block the reabsorption of filtered glucose and sodium in the proximal convoluted tubule (PCT). Increased delivery of sodium and chloride to the macula densa in the juxtaglomerular apparatus stimulates adenosine release, restoring tubuloglomerular feedback (TGF). This induces afferent arteriolar vasoconstriction, reducing intraglomerular hypertension and reversing hyperfiltration.

+-----------------------------------------------------------------------------+
|             GLOMERULAR HEMODYNAMICS: RAAS INHIBITORS vs. SGLT2 INHIBITORS   |
|                                                                             |
|       AFFERENT ARTERIOLE                   EFFERENT ARTERIOLE               |
|             (Inflow)                             (Outflow)                  |
|                |                                    ^                       |
|                v                                    |                       |
|          +-----------+                        +-----------+                 |
|          |  GLOMERULAR CAPILLARY BED (P_gc)   |           |                 |
|          +-----------+                        +-----------+                 |
|                ^                                    ^                       |
|                |                                    |                       |
|   [ SGLT2 INHIBITORS ]                     [ RAAS INHIBITORS ]              |
|   - Increases Na+ to macula densa          - Blocks Angiotensin II effect   |
|   - Causes AFFERENT VASOCONSTRICTION       - Causes EFFERENT VASODILATION   |
|   - Reduces high blood inflow              - Opens outflow valve            |
|                                                                             |
|   ---> SYNERGISTIC RESULT: Dramatic Reduction in Intraglomerular Pressure,  |
|        Halting Albuminuria and Slowing Long-Term eGFR Loss!                |
+-----------------------------------------------------------------------------+

• Clinical Indications & Initiation Thresholds:
  • Initiate in patients with CKD Stage G2–G4 (eGFR $\ge 20\text{--}25\text{ mL/min}/1.73\text{ m}^2$) and $UACR \ge 200\text{ mg/g}$ (or with Type 2 Diabetes at any level of albuminuria).
  • Continuation: Once initiated, SGLT2 inhibitors may be safely continued even if eGFR falls below $20\text{ mL/min}/1.73\text{ m}^2$, until dialysis or kidney transplantation is initiated.
• Adverse Effects & Clinical Safety:
  • Mycotic genital infections (candidiasis; counsel on perineal hygiene).
  • Euglycemic Diabetic Ketoacidosis (euDKA): Hold SGLT2 inhibitors 3 to 4 days prior to elective major surgical procedures or during acute severe medical illness/prolonged fasting.
  • Modest initial "dip" in eGFR ($2\text{--}4\text{ mL/min}$) within 2–4 weeks is reversible and expected.

Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone)

• Mechanism: Finerenone selectively and non-steroidally binds to mineralocorticoid receptors (MR) in the kidney and vasculature with higher affinity than spironolactone or eplerenone, suppressing MR-mediated inflammation, endothelial dysfunction, and fibrosis without causing anti-androgenic side effects (gynecomastia).
• Indications: FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with Type 2 Diabetes associated with CKD ($eGFR \ge 25\text{ mL/min}/1.73\text{ m}^2$ and $UACR \ge 30\text{ mg/g}$) who are already taking maximally tolerated doses of an ACEi or ARB.
• Potassium Thresholds: Baseline serum potassium must be $\le 4.8\text{ mEq/L}$ before initiation. If potassium is $4.9\text{--}5.0\text{ mEq/L}$, optimize other therapies first. Recheck potassium and eGFR at 4 weeks. Withhold if $K^+ > 5.5\text{ mEq/L}$ and resume at a lower dose when $K^+ \le 5.0\text{ mEq/L}$.

---

4. Comprehensive Management of CKD Complications

As functioning nephron mass declines below 50% ($eGFR < 60\text{ mL/min}$), kidneys fail to maintain endocrine, metabolic, and fluid-electrolyte balance, leading to systemic multiorgan complications.

+-----------------------------------------------------------------------------+
|                        CHRONIC COMPLICATIONS OF CKD                         |
|                                                                             |
|   1. ANEMIA OF CKD                                                          |
|      - Deficient peritubular Erythropoietin (EPO) + Iron deficiency.        |
|      - Target TSAT > 20%, Ferritin > 100 ng/mL; ESA target Hb 10.0-11.5 g/dL|
|                                                                             |
|   2. CKD-MINERAL & BONE DISORDER (CKD-MBD)                                  |
|      - Low 1,25(OH)2D3 (Calcitriol) + Phosphate retention -> Low Ca2+      |
|      - Elevated FGF-23 -> Secondary Hyperparathyroidism (PTH elevation)     |
|      - Renal Osteodystrophy & Severe Vascular / Soft Tissue Calcification.  |
|                                                                             |
|   3. METABOLIC ACIDOSIS                                                     |
|      - Inability to excrete fixed H+ and regenerate HCO3- (Serum HCO3 < 22).|
|      - Triggers muscle wasting, bone resorption; Treat with Oral NaHCO3.    |
|                                                                             |
|   4. HYPERKALEMIA                                                           |
|      - Decreased distal K+ excretion; Treat with low-K diet, loop diuretics, |
|        novel potassium binders (Patiromer, Lokelma) to maintain RAASi.     |
|                                                                             |
|   5. VOLUME OVERLOAD & HYPERTENSION                                         |
|      - Sodium and water retention; Loop diuretics (Furosemide, Torsemide).  |
+-----------------------------------------------------------------------------+

Anemia of Chronic Kidney Disease

• Pathophysiology: Primarily caused by decreased synthesis of erythropoietin (EPO) by peritubular interstitial fibroblasts in the renal cortex. Secondary contributors include absolute and functional iron deficiency, systemic inflammation elevating hepcidin (blocking intestinal iron absorption and macrophage iron release), and uremic toxins reducing red blood cell lifespan from 120 days to 60–90 days.
• Diagnostic Evaluation: Evaluated when $Hb < 13.0\text{ g/dL}$ in men or $< 12.0\text{ g/dL}$ in women. Classically presents as a normochromic, normocytic anemia. Required diagnostic workup includes: Complete Blood Count (CBC) with red blood cell indices, reticulocyte count, Serum Ferritin, Transferrin Saturation (TSAT), serum Vitamin B12, and serum Folate.

$TSAT (\%) = \frac{\text{Serum Iron (mcg/dL)}}{\text{Total Iron Binding Capacity [TIBC] (mcg/dL)}} \times 100$

• Iron Repletion Goals (KDIGO):
  • Prior to initiating any ESA therapy, iron deficiency must be corrected. Target a TSAT $> 20\%$ (ideally 20–30%) and Serum Ferritin $> 100\text{ ng/mL}$ in non-dialysis CKD ($> 200\text{ ng/mL}$ in hemodialysis patients).
  • Oral iron (e.g., Ferrous sulfate, Ferrous gluconate, Ferric citrate) can be trialed in non-dialysis CKD; IV iron (e.g., Iron sucrose, Ferric carboxymaltose) is preferred if oral iron is poorly tolerated, ineffective, or if $TSAT \le 20\%$.
• Erythropoiesis-Stimulating Agents (ESAs: Epoetin alfa, Darbepoetin alfa):
  • Initiation Threshold: In non-dialysis CKD, consider ESA initiation only when $Hb < 10.0\text{ g/dL}$, and only after ensuring adequate iron stores ($TSAT > 20\%$, Ferritin $> 100\text{ ng/mL}$).
  • Target Hemoglobin Range: Maintain Hb strictly between $10.0\text{ and }11.5\text{ g/dL}$.

CKD-Mineral and Bone Disorder (CKD-MBD)

• Pathophysiology: As GFR declines below $45\text{ mL/min}$:
  1. Phosphate Retention: Diseased nephrons cannot excrete daily dietary phosphorus, driving hyperphosphatemia.
  2. FGF-23 Elevation: Osteocytes secrete Fibroblast Growth Factor 23 (FGF-23) to force renal phosphate excretion; high FGF-23 further suppresses renal 1-alpha-hydroxylase.
  3. Calcitriol Deficiency: Diminished renal parenchymal 1-alpha-hydroxylase activity reduces conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}_3$ / Calcitriol), decreasing gut calcium absorption and resulting in hypocalcemia.
  4. Secondary Hyperparathyroidism: Hypocalcemia, hyperphosphatemia, and low calcitriol chronically stimulate the parathyroid glands, producing parathyroid hyperplasia and elevated Intact PTH (iPTH).
  5. Skeletal & Vascular Consequences: High PTH drives high-turnover bone disease (Osteitis Fibrosa Cystica), osteomalacia, pathological fractures, severe medial arterial calcification (Monckeberg arteriosclerosis) and Calciphylaxis.

+-----------------------------------------------------------------------------+
|                       CKD-MBD PATHOPHYSIOLOGICAL SPIRAL                     |
|                                                                             |
|                 Declining GFR (< 45 mL/min/1.73 m2)                         |
|                     |                               |                       |
|                     v                               v                       |
|          [Phosphate Retention]             [Loss of 1-alpha-hydroxylase]    |
|                     |                               |                       |
|                     v                               v                       |
|          [Elevated FGF-23]                 [Low Active Calcitriol]          |
|                     |                               |                       |
|                     +---------------+---------------+                       |
|                                     |                                       |
|                                     v                                       |
|                             [HYPOCALCEMIA]                                  |
|                                     |                                       |
|                                     v                                       |
|                 [SECONDARY HYPERPARATHYROIDISM (Elevated PTH)]              |
|                     |                               |                       |
|                     v                               v                       |
|          [Bone Resorption & Fragility]     [Vascular & Soft Tissue Calcif.] |
|          - Osteitis Fibrosa Cystica        - Accelerated Atherosclerosis    |
|          - Adynamic Bone Disease           - Calciphylaxis (Ischemic necrosis|
+-----------------------------------------------------------------------------+

• Management Protocol for CKD-MBD:
  • Dietary Phosphorus Restriction: Limit dietary phosphate to $800\text{--}1,000\text{ mg/day}$ (limit processed foods containing inorganic phosphate additives, colas, dairy, nuts).
  • Phosphate Binders (Taken WITH Meals):
    • Calcium-Based Binders (Calcium Acetate, Calcium Carbonate): First-line if serum calcium is low/normal. Avoid if hypercalcemic or if extensive arterial calcification is present (max elemental calcium $1,500\text{ mg/day}$ from binders).
    • Non-Calcium Binders (Sevelamer Carbonate, Lanthanum Carbonate): Preferred if serum calcium is elevated or patient has documented vascular calcification. (Sevelamer also binds bile acids, moderately lowering LDL-C).
  • Vitamin D & Analogs: Correct nutritional 25-OH Vitamin D deficiency ($<30\text{ ng/mL}$) with Cholecalciferol or Ergocalciferol. If PTH remains elevated despite normal vitamin D and phosphate control, initiate active Vitamin D receptor activators (Calcitriol, Paricalcitol).
  • Calcimimetics (Cinacalcet, Etelcalcetide): Allosterically activate calcium-sensing receptors on the parathyroid gland, suppressing PTH secretion without increasing serum calcium or phosphate (ideal for dialysis patients with hypercalcemic hyperparathyroidism).

Chronic Metabolic Acidosis

• Pathophysiology: Loss of functioning nephrons impairs tubular ammonium ($\text{NH}_4^+$) excretion and endogenous bicarbonate regeneration, resulting in normal anion gap or high anion gap metabolic acidosis.
• Consequences: Chronic acidosis stimulates muscle protein catabolism, accelerates bone demineralization (bone buffers acid, releasing calcium), exacerbates hyperkalemia, and independently accelerates CKD progression.
• Treatment Target: Maintain serum bicarbonate $\ge 22\text{ mEq/L}$ (normal: 22–29 mEq/L).
• Pharmacotherapy: Prescribe oral Sodium Bicarbonate (e.g., 650 mg to 1,300 mg orally twice to three times daily; 1 gram of $\text{NaHCO}_3 \approx 12\text{ mEq}$ of bicarbonate). Monitor for volume overload and hypertension due to sodium load.

Hyperkalemia Management

• Mechanisms: Diminished distal tubular flow and potassium secretion, hyporeninemic hypoaldosteronism, metabolic acidosis shifting intracellular $\text{K}^+$ outward, and renoprotective RAAS inhibitors.
• Strategies to Maintain RAASi Therapy: Avoid discontinuing beneficial ACEi/ARB/MRA therapy for mild-to-moderate hyperkalemia ($5.1\text{--}5.5\text{ mEq/L}$). Instead, implement:
  1. Dietary potassium restriction ($< 2,000\text{--}3,000\text{ mg/day}$).
  2. Addition or up-titration of loop diuretics (e.g., Furosemide $40\text{--}80\text{ mg}$ daily) to promote kaliuresis.
  3. Non-absorbed potassium-binding exchange polymers: Patiromer (Veltassa) ($8.4\text{ g}$ daily with food) or Sodium Zirconium Cyclosilicate (Lokelma / SZC) ($5\text{--}10\text{ g}$ daily). Lokelma binds $\text{K}^+$ in exchange for $\text{Na}^+$ throughout the GI tract, rapidly restoring normokalemia within 1–2 hours without causing colonic necrosis (which occurred with historical sodium polystyrene sulfonate [Kayexalate] in sorbitol).

---

5. Nephrology Referral Triggers & Renal Replacement Therapy Preparation

Standardized KDIGO Nephrology Referral Criteria

The AGPCNP must initiate prompt referral to a nephrologist when any of the following criteria are met:

+-----------------------------------------------------------------------------+
|                  KDIGO NEPHROLOGY REFERRAL TRIGGERS                         |
|                                                                             |
|   * eGFR < 30 mL/min/1.73 m2 (CKD Stage G4 or G5).                          |
|   * Severely Increased Albuminuria: UACR > 300 mg/g (> 30 mg/mmol) or       |
|     Nephrotic-range Proteinuria (> 2,200 mg/g or > 3.5 g/24 hours).         |
|   * Rapid Progression of CKD: Sustained decline in eGFR > 5 mL/min/1.73 m2/ |
|     year, or a > 25% drop in eGFR from baseline within 12 months.           |
|   * Unexplained Microscopic Hematuria with dysmorphic RBCs or RBC casts     |
|     (suggests active glomerulonephritis or vasculitis).                     |
|   * Resistant Hypertension: BP uncontrolled despite >= 3 antihypertensive   |
|     agents of different classes (including a diuretic) at maximum doses.    |
|   * Persistent refractory electrolyte disturbances (hyperkalemia, acidosis).|
|   * Hereditary kidney disease (e.g., ADPKD) or recurrent complex nephrolithiasis.|
|   * Inability to determine underlying etiology of kidney disease.           |
+-----------------------------------------------------------------------------+

Renal Replacement Therapy (RRT) Modalities & Vascular Access Planning

• Timely Preparation: When eGFR declines below $20\text{--}25\text{ mL/min}/1.73\text{ m}^2$ (Stage G4), initiate formal multidisciplinary education regarding RRT options:
  1. Pre-Emptive Kidney Transplantation: Living donor or deceased donor kidney transplantation prior to dialysis initiation provides superior long-term survival, quality of life, and cost-effectiveness compared to dialysis.
  2. Hemodialysis (HD) & Vascular Access Creation:
     • Arteriovenous (AV) Fistula: The gold-standard permanent hemodialysis access (typically radiocephalic or brachiocephalic anastomosis). Constructed in the non-dominant forearm 6 to 12 months prior to anticipated dialysis start to allow adequate vessel arterialization and maturation ($>6\text{ mm}$ diameter, $>600\text{ mL/min}$ blood flow, $<6\text{ mm}$ depth).
     • AV Graft: Synthetic PTFE conduit used when native veins are unsuitable; matures in 2–4 weeks but carries higher thrombosis and infection rates than fistulas.
     • Central Venous Catheter (Tunneled CVC): Highest risk of central vein stenosis, bacteremia, and sepsis; used only as bridge or emergency access.
  3. Peritoneal Dialysis (PD): Continuous Ambulatory PD (CAPD) or Automated PD (APD) via surgically placed Tenckhoff catheter into the peritoneal cavity.